A PYMNTS Company

EU: Mylan rejects Teva’s $40.1 billion buyout offer

By  |  April 27, 2015

Mylan rejected Teva Pharmaceuticals’ $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Mylan said that it won’t think about starting talks unless Teva offers more than $100 per share, far above its current offer of $82 per share. After the rejection Teva said it is committed to completing the deal and that a sale to Teva is Mylan’s best option.

    The rejection comes as both Mylan and Teva look to further consolidate an increasingly competitive generic drug industry. Teva, the world’s largest generic drug company, wants to strengthen its position by buying Mylan.

    Mylan is trying to buy Perrigo of Ireland for about $30 billion in cash and stock, combining its own generic drug business with Perrigo’s position in over-the-counter medications and other nonprescription products. Perrigo has rejected Mylan’s offer, but the Dutch company says it stands by the bid.

     

    Full Content: The New York Times

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.